肠道微生物群
生物
微生物群
生物利用度
代谢性疾病
代谢途径
肠道菌群
代谢组
医学微生物学
微生物生态学
代谢组学
代谢适应
生理学
肠道细菌
代谢综合征
苯丙酮尿症
生物信息学
肠道菌群
新陈代谢
动物模型
代谢控制分析
代谢活性
基因组
作者
Mohammadreza Moghimi,Filippo Martinelli,Paula Walsh,Jonas Widder,Tim Hensen,Luciana Hannibal,Ute Spiekerkoetter,Ines Thiele
标识
DOI:10.1186/s40168-026-02511-9
摘要
Phenylketonuria (PKU) is an inherited metabolic disorder caused by phenylalanine hydroxylase (PAH) deficiency, leading to elevated L-phenylalanine and severe neurological damage if untreated. While phenylalanine-based biomarkers are diagnostic and phenylalanine levels correlate with disease severity, the clinical manifestations of PKU are heterogeneous. To identify additional reliable, potentially novel biomarkers, we used germ-free sex-specific, organ-resolved infant whole-body metabolic models (infant-WBMs) to simulate PAH deficiency and predicted elevated L-phenylalanine and its derivatives, alongside reduced L-tyrosine fluxes, as the product of phenylalanine hydroxylation. To test the reliability of these predicted biomarkers to variations in microbiome composition, we combined the infant-WBMs with gut microbiome models from 48 female and 42 male healthy infants. Upon integrating microbiome data, we found that microbial metabolism significantly increased the predicted L-tyrosine availability, obscuring its utility as a universal biomarker. In ~ 23% of microbiome-PKU models, L-tyrosine fluxes remained low, indicating insufficient microbial compensation. These cases were enriched in Firmicutes and lacked specific Bifidobacterium and Escherichia strains linked to L-tyrosine biosynthesis via the pretyrosine pathway. Shadow price analysis identified microbial species critical for host L-tyrosine metabolism. However, some, such as Bifidobacterium dentium , also contributed to L-phenylalanine synthesis, potentially worsening the PKU phenotype. In contrast, L-phenylalanine, phenylpyruvate, and hydroxyphenylacetic acid remained reliably elevated across all models, validating their diagnostic relevance. Our study demonstrates that microbiome composition can modulate biomarker reliability in PKU, particularly for L-tyrosine. Integrating microbial metabolic models with whole-body physiology enables assessment of biomarker reliability and reveals subpopulations for whom secondary biomarkers or targeted probiotics may be beneficial. This approach offers a powerful framework for refining diagnostics and therapy monitoring in rare metabolic diseases and the development of possible targeted microbiome therapies. Video Abstract
科研通智能强力驱动
Strongly Powered by AbleSci AI